Strategies to improve the cardiovascular risk profile of thiazide-type diuretics as used in the management of hypertension

Expert Opinion on Drug Safety

Volumn 6, Issue 5, 2007, Pages 583-594

  Carter, Barry L ^a,b   Sica, Domenic A ^c  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Antihypertensive therapy; Cardiovascular; Diuretics; Hypertension

Indexed keywords

ALDOSTERONE ANTAGONIST; ALLOPURINOL; AMILORIDE; AMLODIPINE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BENDROFLUMETHIAZIDE; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; EPLERENONE; FUROSEMIDE; HEPARIN; HYDROCHLOROTHIAZIDE; LISINOPRIL; LOOP DIURETIC AGENT; METHYLDOPA; PLACEBO; POTASSIUM; POTASSIUM SPARING DIURETIC AGENT; PROPRANOLOL; RESERPINE; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TRIAMTERENE; UNINDEXED DRUG;

ADD ON THERAPY; ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; HEART ARREST; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE ISCHEMIA; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERURICEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; INSULIN RESISTANCE; LOW DRUG DOSE; MAGNESIUM BLOOD LEVEL; MAGNESIUM URINE LEVEL; MONOTHERAPY; MORTALITY; POTASSIUM BLOOD LEVEL; RECOMMENDED DRUG DOSE; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SIDE EFFECT; SODIUM RESTRICTION; STRATEGIC PLANNING; URIC ACID BLOOD LEVEL; ANIMAL; RISK FACTOR; URINE;

ANIMALS; ANTIHYPERTENSIVE AGENTS; HUMANS; HYPERTENSION; RISK FACTORS; SODIUM CHLORIDE SYMPORTER INHIBITORS;

EID: 35349011200     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.6.5.583     Document Type: Review

References (94)

1. FREIS ED: The cardiovascular risk of diuretic-induced hypokalemia and elevated cholesterol. Ration. Drug Ther. (1986) 20(3):1-6.
2. FREIS ED: The cardiovascular risks of thiazide diuretics. Clin. Pharmacol. Ther. (1986) 39(3):239-244.
3. AMES RP: The effects of antihypertensive drugs on serum lipids and lipoproteins I. Diuretics. Drugs (1986) 32(3):260-278.
4. Mortality after 10 1/2 years for hypertensive participants in the Multiple Risk Factor Intervention Trial. Circulation (1990) 82(5):1616-1628.
5. MOSER M: Why are physicians not prescribing diuretics more frequently in the management of hypertension? JAMA (1998) 279(22):1813-1816.
6. CHOBANIAN AV, BAKRIS GL, BLACK HR et al.: The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA (2003) 289(19):2560-2572.
7. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA (2002) 288(23):2981-2997.
8. SICA DA: Diuretic-related side effects: development and treatment. J. Clin. Hypertens. (Greenwich) (2004) 6(9):532-540.
9. LEREN P, HELGELAND A: Oslo hypertension study. Drugs (1986) 31(Suppl. 1):41-45.
10. WIKSTRAND J, WARNOLD I, OLSSON G et al.: Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY study. JAMA (1988) 259(13):1976-1982.
11. Medical research council trial of treatment of hypertension in older adults: principal results. MRC working party. BMJ (1992) 304(6824):405-412.
12. AMERY A, BIRKENHAGER W, BRIXKO P et al.: Mortality and morbidity results from the European working party on high blood pressure in the elderly trial. Lancet (1985) 1(8442):1349-1354.
13. BORHANI NO, MERCURI M, BORHANI PA et al.: Final outcome results of the multicenter isradipine diuretic atherosclerosis study (MIDAS). A randomized controlled trial. JAMA (1996) 276(10):785-791.
14. BROWN MJ, PALMER CR, CASTAIGNE A et al.: Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: intervention as a goal in hypertension treatment (INSIGHT). Lancet (2000) 356(9227):366-372.
15. WING LM, REID CM, RYAN P et al.: A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N. Engl. J. Med. (2003) 348(7):583-592.
16. ANONYMOUS: Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT collaborative research group [comment]. JAMA (2000) 283(15):1967-1975.
17. Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. Hypertension detection and follow-up program cooperative group. JAMA (1979) 242(23):2562-2571.
18. Five-year findings of the hypertension detection and follow-up program. III. Reduction in stroke incidence among persons with high blood pressure. Hypertension detection and follow-up program cooperative group. JAMA (1982) 247(5):633-638.
19. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the systolic hypertension in the elderly program (SHEP). SHEP cooperative research group. JAMA (1991) 265(24):3255-3264.
20. CARTER BL, ERNST ME, COHEN JD: Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability. Hypertension (2004) 43(1):4-9.
21. ERNST ME, CARTER BL, GOERDT CJ et al.: Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension (2006) 47(3):352-358.
22. SERRO-AZUL JB, DE PAULA RS, GRUPPI C et al.: Effects of chlorthalidone and diltiazem on myocardial ischemia in elderly patients with hypertension and coronary artery disease. Arquivos Brasileiros de Cardiologia (2001) 76(4):268-272.
23. WEIDMANN P, BERETTA-PICCOLI C, MEIER A et al.: Antihypertensive mechanism of diuretic treatment with chlorthalidone. Complementary roles of sympathetic axis and sodium. Kidney Int. (1983) 23(2):320-326.
24. DELL'OMO G, PENNO G, DEL PRATO S, PEDRINELLI R: Chlorthalidone improves endothelial-mediated vascular responses in hypertension complicated by nondiabetic metabolic syndrome. J. Cardiovasc. Pharmacol. Ther. (2005) 10(4):265-272.
25. TWEEDDALE MG, OGILVIE RI, RUEDY J: Antihypertensive and biochemical effects of chlorthalidone. Clin. Pharmacol. Ther. (1977) 22(5 Part 1):519-527.
26. VARDAN S, MEHROTRA KG, MOOKHERJEE S et al.: Efficacy and reduced metabolic side effects of a 15-mg chlorthalidone formulation in the treatment of mild hypertension. A multicenter study. JAMA (1987) 258(4):484-488.
27. MCKENNEY JM, GOODMAN RP, WRIGHT JT Jr et al.: The effect of low-dose hydrochlorothiazide on blood pressure, serum potassium, and lipoproteins. Pharmacotherapy (1986) 6(4):179-184.
28. KOHVAKKA A, SALO H, GORDIN A, EISALO A: Antihypertensive and biochemical effects of different doses of hydrochlorothiazide alone or in combination with triamterene. Acta Med. Scand. (1986) 219(4):381-386.
29. BENGTSSON C, JOHNSSON G, SANNERSTEDT R, WERKO L: Effect of different doses of chlorthalidone on blood pressure, serum potassium, and serum urate. BMJ (1975) 1(5951):197-199.
30. CARNEY S, GILLIES AI, MORGAN T: Optimal dose of a thiazide diuretic. Med. J. Austr. (1976) 2(18):692-693.
31. MORLEDGE JH, ETTINGER B, ARANDA J et al.: Isolated systolic hypertension in the elderly. A placebo-controlled, dose-response evaluation of chlorthalidone. J. Am. Geriatrics Soc. (1986) 34(35):7199-206.
32. MATERSON BJ, OSTER JR, MICHAEL UF et al.: Dose response to chlorthalidone in patients with mild hypertension. Efficacy of a lower dose. Clin. Pharmacol. Ther. (1978) 24(2): 192-198.
33. DEGNBOL B, DORPH S, MARNER T: The effect of different diuretics on elevated blood pressure and serum potassium. Acta Med. Scand. (1973) 193(5):407-410.
34. JOUNELA AJ, LILJA M, LUMME J et al.: Relation between low dose of hydrochlorothiazide, antihypertensive effect and adverse effects. Blood Press. (1994) 3(4):231-235.
35. SAVAGE PJ, PRESSEL SL, CURB JD et al.: Influence of long-term, low-dose, diuretic-based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: the systolic hypertension in the elderly program. SHEP cooperative research group. Arch. Intern. Med. (1998) 158(7):741-751.
36. FRANSE LV, PAHOR M, DI BARI M et al.: Hypokalemia associated with diuretic use and cardiovascular events in the Systolic hypertension in the elderly program [comment]. Hypertension (2000) 35(5):1025-1030.
37. LAKSHMAN MR, REDA DJ, MATERSON BJ, CUSHMAN WC, FREIS ED: Diuretics and β-blockers do not have adverse effects at 1 year on plasma lipid and lipoprotein profiles in men with hypertension. Department of veterans affairs cooperative study group on antihypertensive agents. Arch. Intern. Med. (1999) 159(6):551-558.
38. SISCOVICK DS, RAGHUNATHAN TE, PSATY BM et al.: Diuretic therapy for hypertension and the risk of primary cardiac arrest. N. Engl. J. Med. (1994) 330(26):1852-1857.
39. HOLLAND OB, NIXON JV, KUHNERT L: Diuretic-induced ventricular ectopic activity. Am. J. Med. (1981) 70(4):762-768.
40. KAFKA H, LANGEVIN L, ARMSTRONG PW: Serum magnesium and potassium in acute myocardial infarction. Influence on ventricular arrhythmias. Arch. Intern. Med. (1987) 147(3):465-469.
41. PACKER M: Potential role of potassium as a determinant of morbidity and mortality in patients with systemic hypertension and congestive heart failure. Am. J. Cardiol. (1990) 65(10):E45-E51, discussion E52.
42. DARGIE HJ, CLELAND JG, LECKIE BJ et al.: Relation of arrhythmias and electrolyte abnormalities to survival in patients with severe chronic heart failure. Circulation (1987) 75(5 Part 2):IV98-IV107.
43. NO AUTHORS LISTED: Multiple risk factor intervention trial. Risk factor changes and mortality results. Multiple risk factor intervention trial research group. JAMA (1982) 248(12): 1465-1477.
44. PAPADEMETRIOU V, BURRIS JF, NOTARGIACOMO A, FLETCHER RD, FREIS ED: Thiazide therapy is not a cause of arrhythmia in patients with systemic hypertension. Arch. Intern. Med. (1988) 148(6): 1272-1276.
45. MARTIN BJ, MILLIGAN K: Diuretic-associated hypomagnesemia in the elderly. Arch. Intern. Med. (1987) 147(10):1768-1771.
46. COCCO G, ISELIN HU, STROZZI C, CESANA B, BAUMELER HR: Magnesium depletion in patients on long-term chlorthalidone therapy for essential hypertension. Eur. J. Clin. Pharmacol. (1987) 32(4):335-338.
47. REYES AJ, LEARY WP: Cardiovascular toxicity of diuretics related to magnesium depletion Hum. Toxicol. (1984) 3(5):351-371.
48. WEINMAN EJ, EKNOYAN G, SUKI WN: The influence of the extracellular fluid volume on the tubular reabsorption of uric acid. J. Clin. Invest. (1975) 55(2):283-291.
49. ALDERMAN MH, COHEN H, MADHAVAN S, KIVLIGHN S: Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension (1999) 34(1):144-150.
50. FANG J, ALDERMAN MH: Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National health and nutrition examination survey. JAMA (2000) 283(18):2404-2410.
51. VERDECCHIA P, SCHILLACI G, REBOLDI G et al.: Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA study. Hypertension (2000) 36(6):1072-1078.
52. WANG JG, STAESSEN JA, FAGARD RH et al.: Prognostic significance of serum creatinine and uric acid in older Chinese patients with isolated systolic hypertension. Hypertension (2001) 37(4):1069-1074.
53. FRANSE LV,, PAHOR M, DI BARI M et al.: Serum uric acid, diuretic treatment and risk of cardiovascular events in the systolic hypertension in the elderly program (SHEP). J. Hypertension (2000) 18(8):1149-1154.
54. CULLETON BF, LARSON MG, KANNEL WB, LEVY D: Serum uric acid and risk for cardiovascular disease and death: the Framingham heart study. Ann. Intern. Med. (1999) 131(1):7-13.
55. JOHNSON RJ, KANG DH, FEIG D et al.: Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension (2003) 41(6):1183-1190.
56. AMERY A, BERTHAUX P, BULPITT C et al.: Glucose intolerance during diuretic therapy. Results of trial by the European working party on hypertension in the elderly. Lancet (1978) 1(8066):681-683.
57. ZILLICH AJ, GARG J, BASU S, BAKRIS GL, CARTER BL: Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension (2006) 48(2):219-224.
58. MURPHY MB, LEWIS PJ, KOHNER E, SCHUMER B, DOLLERY CT: Glucose intolerance in hypertensive patients treated with diuretics; a fourteen-year follow-up. Lancet (1982) 2(8311):1293-1295.
59. POLLARE T, LITHELL H, BERNE C: A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N. Engl. J. Med. (1989) 321(13):868-873.
60. GRESS TW, NIETO FJ, SHAHAR E, WOFFORD MR, BRANCATI FL: Hypertension and antihypertensive therapy as risk factors for Type 2 diabetes mellitus. atherosclerosis risk in communities study. N. Engl. J. Med. (2000) 342(13):905-912.
61. CUTLER JA: Thiazide-associated glucose abnormalities: prognosis, etiology, and prevention: is potassium balance the key? Hypertension (2006) 48(2): 198-200.
62. PHILLIPS RA: New-onset diabetes mellitus less deadly than elevated blood pressure? Following the evidence in the administration of thiazide diuretics. Arch. Intern. Med. (2006) 166(20):2174-2176.
63. BARZILAY JI, DAVIS BR, CUTLER JA et al.: Fasting glucose levels and incident Diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Arch. Intern. Med. (2006) 166(20):2191-2201.
64. CURB JD, PRESSEL SL, CUTLER JA et al.: Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic hypertension in the elderly program cooperative research group. JAMA (1996) 276(23): 1886-1892; erratum appears in JAMA (1997); 277(17):1356.
65. VERDECCHIA P, REBOLDI G, ANGELI F et al.: Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension (2004) 43(5):963-969.
66. ROSOLOVA H, MAYER O Jr, REAVEN G: Effect of variations in plasma magnesium concentration on resistance to insulin-mediated glucose disposal in nondiabetic subjects. J. Clin. Endocrinol. Metab. (1997) 82(11):3783-3785.
67. JOHNSON BF, SAUNDERS R, HICKLER R, MARWAHA R, JOHNSON J: The effects of thiazide diuretics upon plasma lipoproteins. J. Hypertens. (1986) 4(2):235-239.
68. GOLDMAN AI, STEELE BW, SCHNAPER HW et al.: Serum lipoprotein levels during chlorthalidone therapy. A veterans administration-national heart, lung, and blood institute cooperative study on antihypertensive therapy: mild hypertension. JAMA (1980) 244(15):1691-1695.
69. LARDINOIS CK, NEUMAN SL: The effects of antihypertensive agents on serum lipids and lipoproteins. Arch. Intern. Med. (1988) 148(6):1280-1288.
70. KASISKE BL, MA JZ, KALIL RS, LOUIS TA: Effects of antihypertensive therapy on serum lipids. Ann. Intern. Med. (1995) 122(2):133-141.
71. WILLIAMS WR, SCHNEIDER KA, BORHANI NO et al.: The relationship between diuretics and serum cholesterol in hypertension detection and follow-up program participants. Am. J. Prevent. Med. (1986) 2(5):248-255.
72. LASSER NL, GRANDITS G, CAGGIULA AW et al.: Effects of antihypertensive therapy on plasma lipids and lipoproteins in the multiple risk factor intervention trial. Am. J. Med. (1984) 76(2A):52-66.
73. GRIMM RH Jr, LEON AS, HUNNINGHAKE DB et al.: Effects of thiazide diuretics on plasma lipids and lipoproteins in mildly hypertensive patients: a double-blind controlled trial. Ann. Int. Med. (1981) 94(1):7-11.
74. GRIMM RH Jr, FLACK JM, GRANDITS GA et al.: Long-term effects on plasma lipids of diet and drugs to treat hypertension. Treatment of mild hypertension study (TOMHS) research group. JAMA (1996) 275(20): 1549-1556.
75. BEERMANN B, GROSCHINSKY-GRIND M: Antihypertensive effect of various doses of hydrochlorothiazide and its relation to the plasma level of the drug. Eur. J. Clin. Pharmacol. (1978) 13(3):195-201.
76. MCLEOD PJ, OGILVIE RI, RUEDY J: Effects of large and small doses of hydrochlorothiazide in hypertensive patients. Clin. Pharmacol. Ther. (1970) 11(5):733-739.
77. CUSHMAN WC, KHATRI I, MATERSON BJ et al.: Treatment of hypertension in the elderly. III. Response of isolated systolic hypertension to various doses of hydrochlorothiazide: results of a department of veterans affairs cooperative study. Department of veterans affairs cooperative study group on antihypertensive agents. Arch. Intern. Med. (1991) 151(10):1954-1960.
78. SKOULARIGIS J, STRUGO V, CHOPAMBA A, SETEKGE S, SARELI P: Low dose hydrochlorothiazide (12.5 to 25 mg daily) as monotherapy in black patients with mild to moderate hypertension. Assessment by ambulatory blood pressure monitoring. Am. J. Hypertens. (1995) 8(10 Part 1):1046-1050.
79. BOWLUS WE, LANGFORD HG: A comparison of the antihypertensive effect of chlorthalidone and hydrochlorothiazide. Clin. Pharmacol. Ther. (1964) 5:708-711.
80. FINNERTY FA Jr: A double-blind study of chlorthalidone and hydrochlorothiazide in an outpatient population of moderate hypertensives. Angiology (1976) 27(12):738-744.
81. CLARK EC, PODOLSKY S, THOMPSON EJ: Double-blind comparison of hydrochlorothiazide plus triameterene therapy versus chlorthalidone therapy in hypertension. South Med. J. (1979) 72(7):798-802.
82. NORDREHAUG JE, VON DER LIPPE G: Hypokalemia and ventricular fibrillation in acute myocardial infarction. Br. Heart. J. (1983) 50(6):525-529.
83. KAPLAN NM, CARNEGIE A, RASKIN P, HELLER JA, SIMMONS M: Potassium supplementation in hypertensive patients with diuretic-induced hypokalemia. N. Engl. J. Med. (1985) 312(12):746-749.
84. MORGAN DB, DAVIDSON C: Hypokalemia and diuretics: an analysis of publications. BMJ (1980) 280(6218):905-908.
85. LAROCHELLE P, LOGAN AG: Hydrochlorothiazide-amiloride versus hydrochlorothiazide alone for essential hypertension: effects on blood pressure and serum potassium level. Can. Med. Assoc. J. (1985) 132(7):801-805.
86. MYERS MG: Hydrochlorothiazide with or without amiloride for hypertension in the elderly. A dose-titration study. Arch.. Intern. Med. (1987) 147(6):1026-1030.
87. HORT JF, WILKINS HM: Changes in blood pressure, serum potassium and electrolytes with a combination of triamterene and a low dose of chlorthalidone. Curr. Med. Res. Opin. (1991) 12(7):430-440.
88. REINHART RA: Magnesium metabolism. A review with special reference to the relationship between intracellular content and serum levels. Arch. Intern. Med. (1988) 148(11):2415-2420.
89. WEINBERGER MH: Influence of an angiotensin converting-enzyme inhibitor on diuretic-induced metabolic effects in hypertension. Hypertension (1983) 5(5 Part 2):III132-III138.
90. SIMUNIC M, RUMBOLDT Z, LJUTIC D, SARDELIC S: Ramipril decreases chlorthalidone-induced loss of magnesium and potassium in hypertensive patients. J. Clin. Pharmacol. (1995) 35(12):1150-1155.
91. SHAHINFAR S, SIMPSON RL, CARIDES AD et al.: Safety of losartan in hypertensive patients with thiazide-induced hyperuricemia. Kidney Int. (1999) 56(5):1879-1885.
92. LANE DA, AHAH S, BEEVERS DG: Low-dose spironolactone in the management of resistant hypertension in man: a surveillance study. J. Hypertens. (2007) 25(4):891-894.
93. SACKS FM, SVETKEY LP, VOLLMER WM et al.: Effects on blood pressure of reduced dietary sodium and the dietary approaches to stop hypertension (DASH) diet. DASH-sodium collaborative research group. N. Engl. J. Med. (2001) 344(1):3-10.
94. VOLLMER WM, SACKS FM, ARD J et al.: Effects of diet and sodium intake on blood pressure: subgroup analysis of the DASH-sodium trial. Ann. Intern. Med. (2001) 135(12):1019-1028.